On September 28, 2026 AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmaceutical company focused on the discovery and development of small molecule therapeutics derived from its boron chemistry platform, reported that the Gates Foundation has awarded an extension of funding to support AN2 Therapeutics’ research activities under its ongoing tuberculosis (TB) research collaboration with GSK focused on the development of boron-based leucyl-tRNA synthetase (LeuRS) inhibitors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
TB remains a major global public health challenge. Globally, TB is the world’s leading cause of death from a single infectious agent and among the top 10 causes of death. 1
"We are grateful for the Gates Foundation’s continued support of this important collaboration with GSK to advance boron-based LeuRS inhibitors for the treatment of tuberculosis," said Vince Hernandez, Senior Vice President of Research & Head of Chemistry of AN2 Therapeutics. "The award of additional funding reflects the progress made by the collaboration and the potential of boron chemistry to enable the discovery of differentiated medicines against challenging infectious disease targets. Together with GSK, we remain committed to advancing innovative approaches that may contribute to the development of new treatment options for people affected by tuberculosis around the world."
Hernandez continued, "This collaboration builds upon decades of experience in boron chemistry and the validation of LeuRS as a therapeutic target. We believe the continued support from the Gates Foundation reinforces the importance of pursuing new approaches to help address one of the world’s most pressing infectious diseases."
Dr. Harmony P. Garges, Chief Global Health Officer, GSK, said: "Tuberculosis continues to have a devastating impact on global health, and new treatment options remain urgently needed. We are pleased to continue our collaboration with AN2 Therapeutics and appreciate the ongoing support of the Gates Foundation as we work to advance innovative science that has the potential to contribute to future TB treatment efforts."
LeuRS is a clinically validated target and is the same target underlying epetraborole (in development for M. abscessus lung disease), ganfeborole (which demonstrated proof-of-concept efficacy in a Phase 2 TB study), and tavaborole, an FDA-approved antifungal. AN2’s boron chemistry platform has demonstrated the ability to generate potent inhibitors of LeuRS and other targets that may not be readily addressed using traditional medicinal chemistry approaches.
About Tuberculosis
Tuberculosis is caused by Mycobacterium tuberculosis and remains one of the leading causes of death from an infectious disease worldwide. In 2024, an estimated 10.7 million people fell ill from TB worldwide.2 Despite existing treatments, significant unmet need remains for new therapeutic options that can further improve outcomes and help address the global burden of disease.
(Press release, AN2 Therapeutics, SEP 28, 2026, View Source [SID1234671124])